Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie